| abstract |
Use of at least one substituted 4-amino-1-phenylbutan-2-ol compound of general formula I ** (Formula) ** where group A represents an aryl or heteroaryl group, groups R1 and R2, identical or different, they represent an alkyl group of 1 to 6 carbon atoms, preferably alkyl of 1 to 3 carbon atoms, or R1 and R2 together form a ring (CH2) 2-6, which can also be substituted with phenyl, the groups R3 and R4, identical or different, represent an alkyl group of 1 to 6 carbon atoms, preferably an alkyl of 1 to 3 carbon atoms, an aryl or an aryl linked by an alkylene group of 1 to 3 carbon atoms, or R3 and R4 together represent (CH2) 3-6 or CH2CH2OCH2CH2, the groups R5, R6 and R7, identical or different, represent H, F, Cl, Br, I, CF3, OR8, SO2CH3, SO2CF3, phenyl, CN, NO2 or a alkyl group of 1 to 6 carbon atoms; R 8 H, an alkyl group of 1 to 6 carbon atoms, preferably an alkyl of 1 to 3 carbon atoms, an aryl, a heteroaryl or an aryl or heteroaryl linked by an alkylene group of 1 to 3 carbon atoms, is represented, in racemate form, enantiomers, diastereoisomers or the corresponding bases or their corresponding salts of physiologically compatible acids as regulators for the ORL1 receptor (similar to the opioid receptor) of the nociceptin / orphanin-FQ-receptor-ORL1 ligand system, for the preparation of a medicament for anxiolysis or diuresis or for the treatment of hypotension or hypertension or senile dementia or Alzheimer's disease or cognitive dysfunctions in general or tinnitus or deafness or epilepsy or obesity or of cachexia. |